Exicure AI Stock Analysis
Want to see XCUR full AI Analyst Report?
Exicure (XCUR) AI Stock Analysis
Exicure
(NASDAQ:XCUR)
The score is driven primarily by severely weak financial performance, including no revenue, ongoing losses, and persistent cash burn. Bearish technical trends, limited valuation support, and ongoing Nasdaq listing risk reinforce the highly speculative profile.
Exicure (XCUR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 55.91K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.75
- Revenue Growth
- ―
- EPS Growth
- 23.05%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Exicure Business Overview & Revenue Model
Company Description
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combi...
How the Company Makes Money
Exicure did not have a sustained commercial product revenue base; its business model was primarily R&D-driven. The company’s cash inflows historically were mainly from financing activities (e.g., issuing equity and related capital-raising transaction...
Exicure Financial Statement Overview
Summary
Extremely weak financial profile: no TTM revenue, persistent operating and net losses, negative operating and free cash flow, and substantial erosion of equity and assets. Zero debt is a limited strength, but ongoing cash burn and a thin equity base create significant funding risk.
Income Statement
8Very NegativeBalance Sheet
32NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 500.00K | 0 | 28.83M | -483.00K |
| Gross Profit | -263.00K | -460.00K | 500.00K | -1.42M | 26.97M | -483.00K |
| EBITDA | -8.55M | -5.12M | -8.85M | -15.54M | 78.00K | -60.63M |
| Net Income | -8.28M | -4.95M | -9.70M | -16.91M | -2.58M | -64.10M |
Balance Sheet | ||||||
| Total Assets | 11.40M | 14.04M | 15.06M | 11.58M | 23.33M | 64.87M |
| Cash, Cash Equivalents and Short-Term Investments | 1.72M | 3.75M | 12.51M | 816.00K | 8.58M | 39.14M |
| Total Debt | 0 | 176.00K | 5.93M | 6.67M | 7.31M | 14.74M |
| Total Liabilities | 10.42M | 10.12M | 8.28M | 8.55M | 8.41M | 53.64M |
| Stockholders Equity | 977.00K | 3.93M | 6.77M | 3.03M | 14.92M | 11.23M |
Cash Flow | ||||||
| Free Cash Flow | -6.38M | -8.56M | -2.91M | -10.36M | -35.67M | -35.79M |
| Operating Cash Flow | -6.70M | -8.55M | -2.91M | -10.36M | -35.66M | -34.82M |
| Investing Cash Flow | 563.00K | -1.81M | 0 | -1.08M | 4.70M | 43.09M |
| Financing Cash Flow | 0 | 1.60M | 13.40M | 3.67M | -3.10M | 1.12M |
Exicure Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Neutral. The current price of 1.07 is above the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.13, and below the 200-day MA of 2.48, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 71.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XCUR.
Exicure Risk Analysis
Exicure disclosed 22 risk factors in its most recent earnings report. Exicure reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksExicure Peers Comparison
Overall Rating
UNCY45Neutral
XCUR38Underperform
CRBU21Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $103.06M | -2.31 | -83.34% | ― | ― | 44.11% | |
| 38Underperform | $7.00M | -0.83 | -237.91% | ― | ― | 23.05% | |
| 21Underperform | $38.12M | -0.34 | -102.74% | ― | 1.60% | 39.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XCUR | Exicure | 1.07 | -2.66 | -71.31% | |
| UNCY | Unicycive Therapeutics, Inc. | 3.70 | -2.22 | -37.50% | |
| CRBU | Caribou Biosciences, Inc. | 0.35 | -1.52 | -81.18% |
Exicure Corporate Events
Exicure Agrees to Sell GPC-100 Program Assets
NeutralOn November 4, 2026, Exicure and its wholly owned subsidiary, GPCR Therapeutics USA Inc., agreed to sell the GPC-100 (burixafor) program assets to Korean company GPCRT Inc. for KRW 6.5 billion, approximately US$4.8 million. The assets included licens...
Exicure Receives Nasdaq Extension Amid Ongoing Listing Risk
NegativeOn June 5, 2026, Exicure, Inc. was notified by Nasdaq that it was not in compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and that it also failed to meet alternative continued listing standards ba...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
